TITLE

Case Study: Posaconazole Treatment of Disseminated Phaeohyphomycosis Due to Exophiala spinifera

AUTHOR(S)
Negroni, Ricardo; Helou, Silvia Haydeé; Petri, Nestor; Robles, Ana María; Arechavala, Alicia; Bianchi, Mario Horacio
PUB. DATE
February 2004
SOURCE
Clinical Infectious Diseases;2/1/2004, Vol. 38 Issue 3, pe15
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
A 41-year-old woman with no known immunosuppression experienced a 12-year period of a relapsing phaeo-hyphomycosis. Despite administration of multiple courses of therapy with standard antifungals, sustained clinical remission was not achieved. A partial response was seen initially with the combination of itraconazole and flucytosine therapy, but the patient did not respond to subsequent treatment. During the patient‘s pregnancy, the mycosis became disseminated, with lymphadenopathy and fever, and was considered life threatening. Despite receipt of parenteral amphotericin B therapy, the patient did not show a clinical response. After premature delivery by cesarean section, treatment with oral posaconazole suspension (800 mg/day) was started. The patient‘s condition improved within 1 week after initiating treatment; therapy was continued for 13 months. During posaconazole treatment, the patient showed a complete clinical response, with negative results of fungal cultures.
ACCESSION #
12080736

 

Related Articles

  • The Echinocandins: Total and Semi-Synthetic Approaches in Antifungal Drug Discovery. Adam R. Renslo // Anti-Infective Agents in Medicinal Chemistry;2007, Vol. 6 Issue 3, p201 

    The echinocandins are a new class of antifungal lipopeptides for the treatment of serious nosocomial mycoses. The three currently approved drugs, caspofungin, micafungin, and anidulafungin, were each discovered through the synthetic modification of echinocandin natural products obtained from...

  • Pharmacists help fight upsurge in fungal infections. Lieder, Tzipora R. // Drug Topics;2/18/2002, Vol. 146 Issue 4, p6 

    Deals with the efforts of pharmacists to develop treatment for fungal infections. Approval of the intravenous Cancidas caspofungin acetate from Merck; Implication of appropriate dosing of antifungals; Variation in the duration of antifungal therapy.

  • Lamisil spray available in Canada to treat fungal skin conditions.  // Dermatology Times;Jul99, Vol. 20 Issue 7, p7 

    Introduces Lamisil spray for treatment of fungal skin conditions manufactured by Novartis Pharmaceuticals Canada Inc. in Toronto Ontario.

  • Monthly itraconazole prevents recurrence of pityriasis versicolor. Guttman, Cheryl // Dermatology Times;Apr2002 Supplement 2, Vol. 23 Issue 4, pS4 

    Investigates the efficacy of itraconazole for the treatment of pityriasis versicolor in Gothenburg, Sweden. Safety option for preventing relapse of the fungal infection; Potency of the regimen against the Malassezia species causing the infection; Concentration of itraconazole to inhibit fungal...

  • Intraconazole use covers various inflammatory diseases. Moyer, Paula // Dermatology Times;Sep2002, Vol. 23 Issue 9, p22 

    Examines the use of itraconazole in treating various inflammatory diseases. Response of disorders with no mycotic components to the drug; Reduction of signs and symptoms of fungal infections due to drug administration; Role of Malassezia species in the pathogenesis of several inflammatory diseases.

  • Efflux Pump Inhibitors: Key to. Jack More Effective Antifungal Treatment?, David // Dermatology Times;Jul98, Vol. 19 Issue 7, p26 

    Considers the effectiveness of efflux pump inhibitors in the treatment of patients which are resistant to antifungal drugs. Physiological significance of efflux pump inhibitors; Therapeutic benefits of efflux; Concerns on issues related to patients with fungal infections.

  • The Cost of Treating Systemic Fungal Infections. van Gool, R. // Drugs;Jan2001 Supplement, Vol. 61 Issue 1, p49 

    The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have...

  • Current Management of Fungal Infections. Meis, J.F.G.M.; Verweij, P.E. // Drugs;Jan2001 Supplement, Vol. 61 Issue 1, p13 

    The management of superficial fungal infections differs significantly from the management of systemic fungal infections. Most superficial infections are treated with topical antifungal agents, the choice of agent being determined by the site and extent of the infection and by the causative...

  • Adjunctive Immune Therapy for Fungal Infections. Casadevall, Arturo; Pirofski, Liise-anne // Clinical Infectious Diseases;10/1/2001, Vol. 33 Issue 7, p1048 

    Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics